Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MA09-hRPE in Stargardt's Macular Dystrophy
NCT01469832Phase 2Completed
- Sponsor
- Astellas Institute for Regenerative Medicine
- Start
- Dec 2011
- Primary completion
- Sep 2015
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
A Phase 2 trial of ASP7317 in Stargardt macular dystrophy, sponsored by Astellas Institute for Regenerative Medicine. Started Dec 2011; status: completed.
02
Drugs
ASP7317
03
Conditions
Stargardt macular dystrophy
Beyond the preview
Go deeper on NCT01469832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01469832.